GPI 1485 is a product candidate that belongs to a class of small molecule compounds called neuroimmunophilin ligands. In preclinical experiments, neuroimmunophilin ligands have been shown to repair and regenerate... GPI 1485 is being studied in phase 2 clinical trials for the treatment of Parkinson's disease and post-prostatectomy erectile dysfunction and in pre-clinical development for HIV related dementia and neuropathy.
- Mechanism
- Curator reviewed
GPI 1485 belongs to a class of small molecule compounds called neuroimmunophilin ligands which are a family of binding proteins that are highly conserved in nature and mediate the actions of immunosuppressant drugs. The FK-506-binding protein (FKBP) subclass of immunophilin bind FK-506 and rapamycin and are of particular interest due to their potent neurotrophic activity.
- Primary indication
- Investigated for use/treatment in erectile dysfunction and parkinson's disease.Curator reviewed
- Formula / weight
- C12H19NO4 · 241.287 g/mol (avg)
- Code names
- GPI-1485
Resolves to
FOPALECPEUVCTL-QMMMGPOBSA-NSMILESCCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(O)=OWhat you can answer from here — as of January 29, 2025
Which drugs share a target with GPI-1485, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account